Literature DB >> 20179739

Polymorphisms in the IL2, IL2RA and IL2RB genes in multiple sclerosis risk.

María L Cavanillas1, Antonio Alcina, Concepción Núñez, Virginia de las Heras, Miguel Fernández-Arquero, Manuel Bartolomé, Emilio G de la Concha, Oscar Fernández, Rafael Arroyo, Fuencisla Matesanz, Elena Urcelay.   

Abstract

Interleukin (IL)-2/IL-2R signalling promotes proliferation and survival of activated T cells and has an essential non-redundant role in the production of regulatory T cells. Associations with different autoimmune diseases of polymorphisms in a linkage disequilibrium block in which the IL2/IL21 genes map (4q27), and also in genes encoding the IL2RA and IL2RB subunits (located in 10p15 and 22q13, respectively), were identified through genome-wide studies. Polymorphisms in these three genes were studied in 430 multiple sclerosis (MS) patients and in 550 ethnically matched controls from Madrid (Spain). Replication and meta-analysis with results from an independent cohort of 771 MS patients and 759 controls from Andalucía (Spain) confirmed the association of polymorphisms in the IL2RA gene (P(Mantel-Haenszel,) odds ratio (OR)(M-H) (95% confidence interval, CI) for rs2104286: 0.0001, 0.75 (0.65-0.87); for rs11594656/rs35285258: 0.004, 1.19 (1.06-1.34); for rs41295061: 0.03, 0.77 (0.60-0.98)); showed a trend for association of the IL2/IL21 rs6822844 (P(M-H)=0.07, OR(M-H) (95% CI)=0.86 (0.73-1.01)), but did not corroborate the association for IL2RB. Regression analyses of the combined Spanish cohort revealed the independence of two IL2RA association signals: rs2104286 and rs11594656/rs35285258. The relevant role of the IL2RA gene on MS susceptibility adds support to its common effect on autoimmune risk and the suggestive association of IL2/IL21 warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179739      PMCID: PMC2987360          DOI: 10.1038/ejhg.2010.15

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  33 in total

1.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Authors:  Bibiana Bielekova; Marta Catalfamo; Susan Reichert-Scrivner; Amy Packer; Magdalena Cerna; Thomas A Waldmann; Henry McFarland; Pierre A Henkart; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

2.  IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitis.

Authors:  Michal Irony-Tur-Sinai; Michal Lichtenstein; Talma Brenner; Haya Lorberboum-Galski
Journal:  Int Immunopharmacol       Date:  2009-07-22       Impact factor: 4.932

3.  Association between HL-A antigens and measles antibody in multiple sclerosis.

Authors:  C Jersild; T Ammitzboll; J Clausen; T Fog
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

4.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

5.  Allelic expression and interleukin-2 polymorphisms in multiple sclerosis.

Authors:  F Matesanz; M Fedetz; M Collado-Romero; O Fernández; M Guerrero; C Delgado; A Alcina
Journal:  J Neuroimmunol       Date:  2001-09-03       Impact factor: 3.478

6.  Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients.

Authors:  U Feger; C Luther; S Poeschel; A Melms; E Tolosa; H Wiendl
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

Review 7.  Tolerance, not immunity, crucially depends on IL-2.

Authors:  Thomas R Malek; Allison L Bayer
Journal:  Nat Rev Immunol       Date:  2004-09       Impact factor: 53.106

8.  Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms.

Authors:  Adrian Vella; Jason D Cooper; Christopher E Lowe; Neil Walker; Sarah Nutland; Barry Widmer; Richard Jones; Susan M Ring; Wendy McArdle; Marcus E Pembrey; David P Strachan; David B Dunger; Rebecca C J Twells; David G Clayton; John A Todd
Journal:  Am J Hum Genet       Date:  2005-03-17       Impact factor: 11.025

9.  Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period.

Authors:  Allison L Bayer; Aixin Yu; Dennis Adeegbe; Thomas R Malek
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

10.  Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.

Authors:  Vissia Viglietta; Clare Baecher-Allan; Howard L Weiner; David A Hafler
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

View more
  15 in total

1.  Determination of the real effect of genes identified in GWAS: the example of IL2RA in multiple sclerosis.

Authors:  Marie-Claude Babron; Hervé Perdry; Adam E Handel; Sreeram V Ramagopalan; Vincent Damotte; Bertrand Fontaine; Bertram Müller-Myhsok; George C Ebers; Françoise Clerget-Darpoux
Journal:  Eur J Hum Genet       Date:  2011-11-16       Impact factor: 4.246

2.  Dynamic demethylation of the IL2RA promoter during in vitro CD4+ T cell activation in association with IL2RA expression.

Authors:  Marie-Pierre Belot; Anne-Laure Castell; Sophie Le Fur; Pierre Bougnères
Journal:  Epigenetics       Date:  2018-08-10       Impact factor: 4.528

Review 3.  Cytokine gene polymorphisms and human autoimmune disease in the era of genome-wide association studies.

Authors:  Koen Vandenbroeck
Journal:  J Interferon Cytokine Res       Date:  2011-12-22       Impact factor: 2.607

4.  Regulatory T cell proliferative potential is impaired in human autoimmune disease.

Authors:  Fortunata Carbone; Veronica De Rosa; Pietro B Carrieri; Silvana Montella; Dario Bruzzese; Antonio Porcellini; Claudio Procaccini; Antonio La Cava; Giuseppe Matarese
Journal:  Nat Med       Date:  2013-12-08       Impact factor: 53.440

5.  Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function.

Authors:  Garima Garg; Jennifer R Tyler; Jennie H M Yang; Antony J Cutler; Kate Downes; Marcin Pekalski; Gwynneth L Bell; Sarah Nutland; Mark Peakman; John A Todd; Linda S Wicker; Timothy I M Tree
Journal:  J Immunol       Date:  2012-03-28       Impact factor: 5.422

6.  Analysis of Single Nucleotide Polymorphisms in HLA-DRA, IL2RA , and HMGB1 Genes in Multiple Sclerosis.

Authors:  Mohsen Asouri; Hamid Alinejad Rokni; Mohammad Ali Sahraian; Sadegh Fattahi; Nima Motamed; Rozita Doosti; Hamzeh Rahimi; Maryam Lotfi; Azam Moslemi; Morteza Karimpoor; Fereidoun Mahboudi; Haleh Akhavan-Niaki
Journal:  Rep Biochem Mol Biol       Date:  2020-07

7.  Compensatory T-cell regulation in unaffected relatives of SLE patients, and opposite IL-2/CD25-mediated effects suggested by coreferentiality modeling.

Authors:  Constantin Fesel; Marta Barreto; Ricardo C Ferreira; Nuno Costa; Lara L Venda; Clara Pereira; Claudia Carvalho; Maria Francisca Morães-Fontes; Carlos M Ferreira; Carlos Vasconcelos; João F Viana; Eugenia Santos; Berta Martins; Jocelyne Demengeot; Astrid M Vicente
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

Review 8.  Functional profiling of the gut microbiome in disease-associated inflammation.

Authors:  Daniela Börnigen; Xochitl C Morgan; Eric A Franzosa; Boyu Ren; Ramnik J Xavier; Wendy S Garrett; Curtis Huttenhower
Journal:  Genome Med       Date:  2013-07-31       Impact factor: 11.117

9.  Association of HLA-DRA and IL2RA Polymorphisms with the Severity and Relapses Rate of Multiple Sclerosis in an Iranian Population.

Authors:  Mohsen Asouri; Hamid Alinejad Rokni; Mohammad Ali Sahraian; Sadegh Fattahi; Nima Motamed; Rozita Doosti; Galia Amirbozorgi; Morteza Karimpoor; Fereidoun Mahboudi; Haleh Akhavan-Niaki
Journal:  Rep Biochem Mol Biol       Date:  2020-07

Review 10.  Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis.

Authors:  Stanley Cohan
Journal:  Biologics       Date:  2016-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.